Molecular linkages between diabetes and Alzheimer's disease: Current scenario and future prospects

CNS and Neurological Disorders - Drug Targets

Volumn 13, Issue 2, 2014, Pages 290-298

  Dar, Tanveer A ^a   Sheikh, Ishfaq A ^b   Ganie, Showkat A ^a   Ali, Riyasat ^c   Singh, Laishram R ^d   Gan, Siew Hua ^e   Kamal, Mohammad A ^b   Zargar, Mohammad A ^a  

^a UNIVERSITY OF KASHMIR   (India)

^b KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^c ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^d UNIVERSITY OF DELHI   (India)

^e SCHOOL OF MEDICAL SCIENCES   (Malaysia)

Author keywords

Acetylcholine; Alzheimer's diseases; Amyloid peptide; Conformational diseases; Diabetes; Inflammation; Insulin resistance; Mitochondrial dysfunction; Oxidative stress; Telomere shortening

Indexed keywords

AMYLIN; ANTIDIABETIC AGENT; CHOLINE ACETYLTRANSFERASE; FREE RADICAL; HOMOCYSTEINE; INSULIN; LEPTIN; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; TACRINE; TAU PROTEIN;

AGING; ALZHEIMER DISEASE; APOPTOSIS; ARTICLE; DISEASE ASSOCIATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DYSLIPIDEMIA; GLUCOSE METABOLISM; HOMOCYSTINURIA; HUMAN; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; MOLECULAR PATHOLOGY; NERVE DEGENERATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PHOSPHORYLATION; PROTEIN FOLDING; PROTEIN GLYCOSYLATION; PROTEOMICS; SIGNAL TRANSDUCTION; TELOMERE SHORTENING; ANIMAL; BIOLOGICAL MODEL; METABOLISM;

ALZHEIMER DISEASE; ANIMALS; DIABETES MELLITUS, TYPE 2; HUMANS; MODELS, BIOLOGICAL;

EID: 84904474085     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/18715273113126660135     Document Type: Article

References (105)

1. Mayeux R. Epidemiology of neurodegeneration. Annu Rev Neurosci 2003; 26: 81-104.
2. Jennifer BP, Martin R, Colleen F, et al. Amyloid Plaque and Neurofibrillary Tangle Pathology in a Regulatable Mouse Model of Alzheimer's Disease. Am J Pathol 2008; 173: 762-72.
3. Götz J, Schild A, Hoerndli F, Pennanen L. Amyloid-induced neurofibrillary tangle formation in Alzheimer's disease: insight from transgenic mouse and tissue-culture models. Int J Dev Neurosci 2004; 22: 453-65.
4. Prabakar S, Porkumaran K. An Investigation of volumetric and corpus callosum dimension to detect brain disorders. J Biomed Sci Engin 2012; 5: 369-77.
5. Wilcox G. Insulin and Insulin Resistance. Clin Biochem Rev 2005; 26: 19-39.
6. Hunter SJ, Garvey WT. Insulin action and insulin resistance: diseases involving defects in insulin receptors, signal transduction, and the glucose transport effector system. Am J Med 1998; 105: 331-45.
7. Cao P, Tu LH, Abedini A, et al. Sensitivity of amyloid formation by human islet amyloid polypeptide to mutations at residue 20. J Mol Biol 2012; 421: 282-95.
8. Schubert M, Brazil DP, Burks DJ, et al. Insulin receptor substrate-2 deficiency impairs brain growth and promotes tau phosphorylation. J Neurosci 2003; 23: 7084-92.
9. Havrankova J, Jesse R, Michael B. Insulin receptors are widely distributed in the central nervous system of the rat. Nature 1978; 272: 827-9.
10. Shu-Ling C, Hollis TC. Insulin receptor signalling in the development of neuronal structure and function. Neural Develop 2010; 5: 7-11.
11. Leibson CL, Rocca WA, Hanson VA, et al. Risk of Dementia among Persons with Diabetes Mellitus: A Population-based Cohort Study. Am J Epidemiol 1997; 145(4): 301-8.
12. Peila R, Rodriguez BL, Launer LJ. Type 2 Diabetes, APOE gene, and the risk for dementia and related pathologies. Diabetes 2002; 51: 1256-62.
13. Akomolafe A, Beiser A, Meigs JB, et al. Diabetes mellitus and risk of developing Alzheimer disease: results from the Framingham Study. Arch Neurol 2006; 63: 1551-5.
14. Steen E, Terry BM, Rivera EJ, et al. Impaired insulin and insulinlike growth factor expression and signalling mechanisms in Alzheimer's disease-is this type 3 diabetes? J Alzheimers Dis 2005; 7: 63-80.
15. Whiting DR, Guariguata L, Weil C, Shaw J. IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011; 94: 311-21.
16. Banks W. A The source of cerebral insulin. Eur J Pharmacol 2004; 490: 5-12.
17. Bosco D, Fava A, Plastino M, Montalcini T, Pujia A. Possible implications of insulin resistance and glucose metabolism in Alzheimer's disease pathogenesis. J Cell Mol Med 2011; 15: 1807-21.
18. Weiping H, Cai Li. Linking type 2 diabetes and Alzheimer's disease, Proc Nat Acad Sci USA 2010; 107: 6557-8.
19. Craft S, Peskind E, Schwartz MW, et al. Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology 1998; 50: 164-8.
20. Reaven G. M Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-607.
21. Purello F, Rabuazzo AM. Metabolic factors that affect beta-cell function and survival. Diabetes Nutr Metab 2000; 13: 84-91.
22. Clarke DW, Boyd FT, Kappy MS, Raizada MK. Insulin binds to specific receptors and stimulates 2-deoxy-D-glucose uptake in cultured glial cells from rat brain. J Biol Chem 1984; 259: 11672-5.
23. Dringen R, Hamprecht B. Glucose, insulin, and insulin-like growth factor I regulate the glycogen content of astroglia-rich primary cultures. J Neurochem 1992; 58: 511-7.
24. Craft S, Asthana S, Schellenberg G. Insulin metabolism in Alzheimer's disease differs according to apolipoprotein E genotype and gender. Neuroendocrinol 1999; 70: 146-52.
25. Werner H, Raizada MK, Mudd LM. Regulation of rat brain/HepG2 glucose transporter gene expression by insulin and insulin-like growth factor-I in primary cultures of neuronal and glial cells. Endocrinology 1989; 125: 314-20.
26. Rivera EJ, Goldin A, Fulmer N, et al. Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. J Alzheimers Dis 2005; 8: 247-68.
27. Park SA. A common pathogenic mechanism linking type-2 diabetes and Alzheimer's disease: evidence from animal models. J Clin Neurol 2011; 7: 10-8.
28. Zhao WQ, De Felice FG, Fernandez S, et al. Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB J 2008; 22: 246-60.
29. Gasparini L, Gouras GK, Wang R, et al. Stimulation of betaamyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling. J Neurosci 2001; 21: 2561-70.
30. Watson GS, Craft S. The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment. CNS Drugs 2003; 17: 27-45.
31. Hak AE, Pols HA, Stehouwer CD, et al. Markers of inflammation and cellular adhesion molecules in relation to insulin resistance in non-diabetic elderly: the Rotterdam study. J Clin Endocrinol Metab 2001; 86: 4398-405.
32. Van de Ree MA, Huisman MV, Princen HM, Meinders AE, Kluft C. Strong decrease of high sensitivity C-reactive protein with highdose atorvastatin in patients with type 2 diabetes mellitus. Atherosclerosis 2003; 166: 129-35.
33. Hotamisligil GS. Inflammatory pathways and insulin action. Int J Obes Relat Metab Disord 2003; 27: 53-5.
34. Akter K, Lanza EA, Martin SA, et al. Diabetes mellitus and Alzheimer's disease: shared pathology and treatment? Br J Clin Pharmacol 2011; 71: 365-76.
35. Schmidt R, Schmidt H, Curb JD, et al. Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study. Ann Neurol 2002; 52: 168-74.
36. Engelhart MJ, Geerlings MI, Meijer J, et al. Inflammatory proteins in plasma and the risk of dementia: the Rotterdam study. Arch Neurol 2004; 61: 668-72.
37. Takeda S, Sato N, Uchio-Yamada K, et al. Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Aβ deposition in an Alzheimer mouse model with diabetes. Proc Natl Acad Sci USA 2010; 107: 7036-41.
38. Anthony JC, Breitner JC, Zandi PP, et al. Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists: the Cache County study. Neurology 2000; 54: 2066-71.
39. Broe GA, Grayson DA, Creasey HM, et al. Anti-inflammatory drugs protect against Alzheimer disease at low doses. Arch Neurol 2000; 57: 1586-91.
40. Kroner Z. The relationship between Alzheimer's disease and diabetes: type 3 diabetes? Altern Med Rev 2009; 14: 373-9.
41. Sreedhar G, Thota H, Alam AR, et al. Alzheimers disease and type 2 diabetes mellitus: cholinesterase connection? Lipids Health Dis 2006; 5: 28-33.
42. Kaplay SS. Acetylcholinesterase and butrylcholinesterase of developing human brain. Biol Neonate 1976; 28: 65-73.
43. Borovikova LV, Ivanova S, Zhang M, et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 2000; 405: 458-62.
44. Martim AC, Sanders RA, Watkins JB. Diabetes, oxidative stress, and antioxidants: a review. J Biochem Mol Toxicol 2003; 17: 24-38.
45. Mattson MP, Gleichmann M, Cheng A. Mitochondria in neuroplasticity and neurological disorders. Neuron 2008; 60: 748-66.
46. Jiang D, Li X, Williams R, et al. Ternary complexes of iron, amyloid-beta, and nitrilotriacetic acid: binding affinities, redox properties, and relevance to iron-induced oxidative stress in Alzheimer's disease. Biochemistry 2009; 48: 7939-47.
47. Markesbery WR. Oxidative stress hypothesis in Alzheimer's Disease. Free Radic Biol Med 1997; 23: 134-47.
48. Vitek MP, Bhattacharya K, Glendening JM, et al. Advanced glycation end products contribute to amyloidosis in Alzheimer's disease. Proc Natl Acad Sci USA 1994; 91: 4766-70.
49. Moreira PI, Duarte AI, Santos MS, Rego AC, Oliveira CR. An integrative view of the role of oxidative stress, mitochondria and insulin in Alzheimer's disease. J Alzheimers Dis 2009; 16: 741-61.
50. Chen H, Chan DC. Mitochondrial dynamics-fusion, fission, movement, and mitophagy-in neurodegenerative diseases. Hum Mol Genet 2009; 18: R169-76.
51. Perez-Matute P, Zulet MA, Martinez JA. Reactive species and diabetes: counteracting oxidative stress to improve health. Curr Opin Pharmacol 2009; 9: 771-9.
52. Novelli A, Reilly JA, Lysko PG, Henneberry RC. Glutamate becomes neurotoxic via the N-methyl-D-aspartate receptor when intracellular energy levels are reduced. Brain Res 1988; 451: 205-12.
53. Takeuchi M, Yamagishi S. Possible involvement of advanced glycation end-products (AGEs) in the pathogenesis of Alzheimer's disease. Curr Pharm Des 2008; 14: 973-8.
54. Takeuchi M, Yamagishi S. Alternative routes for the formation of glyceraldehyde-derived AGEs (TAGE) in vivo. Med Hypotheses 2004; 63: 453-5.
55. Yamagishi S, Takeuchi M, Inagaki Y, Nakamura K, Imaizumi T. Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy. Int J Clin Pharmacol Res 2003; 23: 129-34.
56. Smith MA, Harris PL, Sayre LM, Perry G. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci USA 1997; 94: 9866-8.
57. Munch G, Schinzel R, Loske C, et al. Alzheimer's disease - synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts. J Neural Transm 1998; 105: 439-61.
58. Valente T, Gella A, Fernandez-Busquets X, Unzeta M, Durany N. Immuno-histochemical analysis of human brain suggests pathological synergism of Alzheimer's disease and diabetes mellitus. Neurobiol Dis 2010; 37: 67-76.
59. Anoop A, Pradeep KS, Reeba SJ, Samir KM. CSF Biomarkers for Alzheimer's Disease Diagnosis, Int J Alzheimer Dis 2010; 1-12.
60. Meha FA, Rizwana SW. A review of biochemical markers for early diagnosis of Alzheimer's disease, Am J Neurosci 2012; 3: 54-62.
61. Di Paolo G, Kim TW. Linking lipids to Alzheimer's disease: cholesterol and beyond. Nat Rev Neurosci 2011; 12: 284-96.
62. Taskinen MR. Diabetic dyslipidemia. Atherosclerosis 2002; 3: 47-51.
63. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365: 1415-28.
64. Hayashi H. Lipid metabolism and glial lipoproteins in the central nervous system. Biol Pharm Bull 2011; 34: 453-61.
65. Jenkins AJ, Best, JD, Klein RL, Lyons TJ. Lipoproteins, glycoxidation and diabetic angiopathy. Diabetes Metabol Res Rev 2004; 20: 349-68.
66. Lutjohann D. Cholesterol metabolism in the brain: importance of 24S-hydroxylation. Acta Neurol Scand 2006; 185: 33-42.
67. Hamel FG, Upward JL, Bennett RG. In vitro inhibition of insulindegrading enzyme by long-chain fatty acids and their coenzyme A thioesters. Endocrinology 2003; 144: 2404-8.
68. Hillered L, Chan PH. Role of arachidonic acid and other free fatty acids in mitochondrial dysfunction in brain ischemia. J Neurosci Res 1988; 20: 451-6.
69. Zhang JH, Wen-Jun S, Salman A. Cellular cholesterol delivery, intracellular processing and utilization for biosynthesis of steroid hormones. Nutr Metab 2010; 7, 47-52.
70. Ta-Yuan C, Catherine CY, Chang NO, Yoshio Y. Cholesterol Sensing, Trafficking, and Esterification. Annu Rev Cell Dev Biol 2006; 22: 129-57.
71. Hatters DM, Zhong N, Rutenber E, Weisgraber KH. Aminoterminal domain stability mediates apolipoprotein E aggregation into neurotoxic fibrils. J Mol Biol 2006; 361: 932-44.
72. Jiang Q, Lee CY, Mandrekar S, et al. ApoE promotes the proteolytic degradation of Abeta. Neuron 2008; 58: 681-93.
73. Brecht WJ, Harris FM, Chang S, et al. Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice. J Neurosci Off J Soc Neurosci 2004; 24: 2527-34.
74. Nicolls MR, D'Antonio JM, Hutton JC, et al. Proteomics as a tool for discovery: proteins implicated in Alzheimer's disease are highly expressed in normal pancreatic islets. J Proteome Res 2003; 2: 199-205.
75. David DC, Ittner LM, Gehrig P, et al. Beta-amyloid treatment of two complementary P301L tau-expressing Alzheimer's disease models reveals similar deregulated cellular processes. Proteomics 2006; 6: 6566-77.
76. Selkoe DJ. Alzheimer's disease: Genes, proteins, and therapy. Physiol Rev 2001; 81: 741-66.
77. Avial J. Tau phosphorylation and aggregation in Alzheimer's disease pathology. FEBS Lett 2006; 580: 2922-7.
78. Hoppener JW, Ahren B, Lips CJ. Islets amyloid and type 2 diabetes mellitus. N Eng J Med 2000; 343: 411-9.
79. Hoppener JW, Lips CJ. Role of Islets amyloid in type 2 diabetes mellitus. Int J Biochem Cell Biol 2006; 38: 726-36.
80. Zhang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372: 425-32.
81. Harvey J. Leptin regulation of neuronal excitability and cognitive function. Curr Opin Pharmacol 2007; 7: 643-7.
82. Morrison CD. Leptin signalling in brain: A link between nutrition and cognition? Biochem Biophys Acta 2009; 1792: 401-8.
83. Chiu SL, Chen CM, Cline HT. Insulin receptor signalling regulates synapse number, dendriticplaticity and circuit function in vivo. Neuron 2008; 58: 708-19.
84. Eckmann EA, Ecman CB. Abeta-degrading enzymes: Modulators of Alzheimer's disease athogenesis and targets for therapeutic intervention. Biochem Soc Trans 2005; 33: 1101-5.
85. Fewlass DC. Obesity related leptin regulates Alzheimers Abeta. FASEB J 2004; 18: 1870-8.
86. Phiel CJ, Wilson CA, Lee VM, Klein PS. GSK-3alpha regulates production of Alzheimers diseases amyloid beta peptides. Nature 2003; 423: 435-9.
87. Kuhlow D, Florian S, von Figura G, et al. Telomerase deficiency impairs glucose metabolism and insulin secretion. Aging 2010; 2(10): 650-8.
88. Mulder H. Is shortening of telomeres the missing link between ageing and type 2 diabetes epidemic. Aging 2010; 2: 634-6.
89. Troen AM. The central nervous system in animal models of hyperhomocysteinemia. Progr Neuropsychopharmacol Biol Psychiatry 2005; 29: 1140-51.
90. Seshadri SMD, Beiser A, Selhub J, et al. Plasma Homocysteine as a Risk Factor for Dementia and Alzheimer's Disease. New Engl J Med 2002; 346: 476-83.
91. Sainani GS, Karatela RA. Plasma Leptin in Insulin-Resistant and Insulin-Nonresistant Coronary Artery Disease and Its Association with Cardio-Metabolic Risk Factors among Asian Indians. Metab Syndr Relat Disord 2009; 7: 335-40.
92. Gallistl S, Wolfgang E, Karl S, Martin B, Harald M. Insulin is an independent correlate of plasma homocysteine levels in obese children and adolescents. Diabetes Care 2000; 23: 1348-52.
93. Chiang EP, Wang YC, Chen WW, Tang FY. Effects of Insulin and Glucose on Cellular Metabolic Fluxes in Homocysteine Transsulfuration, Remethylation, S-Adenosylmethionine Synthesis, and Global Deoxyribonucleic Acid Methylation. J Clin Endocrinol Metab 2009; 94: 1017-25.
94. Strum JC, Shehee R, Virley D, et al. Rosiglitazone induces mitochondrial biogenesis in mouse brain. J Alzheimers Dis 2007; 11: 45-51.
95. Nicolakakis N, Hamel E. Neurovascular function in Alzheimer's disease patients and experimental models. J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab 2011; 31: 1354-70.
96. Sodhi RK, Singh N, Jaggi AS. Neuroprotective mechanisms of peroxisome proliferator-activated receptor agonists in Alzheimer's disease. Naunyn Schmiedeberg's Arch Pharmacol 2011; 384: 115-24.
97. Zhao Q, Matsumoto K, Tsuneyama K, et al. Diabetes-induced central cholinergic neuronal loss and cognitive deficit are attenuated by tacrine and a Chinese herbal prescription, kangen-karyu: elucidation in type 2 diabetes db/db mice. J Pharmacol Sci 2011; 117: 230-42.
98. Markaki M, Tavernarakis N. Modeling human diseases in Caenorhabditis elegans. Biotechnol J 2010; 5: 1261-76.
99. Hartman PS, Naoaki I. Chromosome dosage as a life span determinant in Caenorhabiditis elegans. Mech Ageing Dev 2007; 28: 437-43.
100. Andreas S, Georgi K, Farastuk B, et al. C elegans as Model for the Study of High Glucose-Mediated Life Span Reduction. Diabetes 2009; 58: 2450-6.
101. Rachel K, Coleen TM. The role of insulin/IGF-like signaling in C elegans longevity and aging. Dis Models Mech 2010; 3: 1-5.
102. Morcos M, Hutter H. The model Caenorhabditis elegans in diabetes mellitus and Alzheimer's disease. J Alzheimers Dis 2009; 16: 897-908.
103. Paula LM, Parthsarathy P, Emilie F, Christian H. The Diabetes Drug Liraglutide Prevents Degenerative Processes in a Mouse Model of Alzheimer's Disease. J Neurosci 2011; 31: 6587-94.
104. Wu Z, Smith JV, Paramasivam V, et al. Ginkgo biloba extract EGb 761 increases stress resistance and extends life span of Caenorhabditis elegans. Cell Mol Biol 2002; 48: 725-31.
105. Dostal V, Link CD. Assaying beta-amyloid toxicity using a transgenic C elegans model. J Vis Exp 2010; 44: 11-6.